Lv4
748 积分 2024-06-06 加入
Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial
26天前
已完结
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study
1个月前
已完结
BIO89-100, a novel glycoPEGylated FGF21 Analog, Demonstrates Triglyceride Reduction and Broad Metabolic Effects in Spontaneously Diabetic Obese Cynomolgus Monkeys
1个月前
已关闭
Bridging Studies in Preclinical Pharmaceutical Safety Assessment
2个月前
已关闭
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
2个月前
已完结
Antibody–peptide conjugates deliver covalent inhibitors blocking oncogenic cathepsins
2个月前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
4个月前
已完结
Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial
4个月前
已完结
The Gut-Bone Axis in Diabetes
5个月前
已完结
皖公网安备34019202002308
